摘要
目的观察长春瑞滨（诺维本，NVB）治疗老年晚期非小细胞肺癌患者的临床疗效及不良反应。方法对住院治疗的20例老年晚期非小细胞肺癌患者采取长春瑞滨25mg／m^2，第1，8天，21～28d为一个周期，每例患者至少化疗2个周期，按标准评价疗效和毒副作用。结果可评价患者20例，有效率为35．0％，中位生存期为6个月，一年生存率为29．0％。主要毒性反应为骨髓抑制，多为Ⅰ～Ⅱ度反应。结论单药长春瑞滨化疗方案是治疗老年晚期NSCLC的一个疗效较好、毒性较低的一线方案。
Objective To observe the clinical efficacy and side effects of navelbine（NVB） regimen in treatment of old patients with advanced non-small-cell lung cancer（NSCLC）. Methods Twenty old patients with unresectable NSCLC were enrolled in this study. Navelhine 25 mg/m2 was administered on days 1,8 intravenously every 3-4 weeks as a cycle and each patient received at least 2 cycles. Results In the 20 evaluable cases, the response rate was 35%, median survival time was 6 months and 1-year survival rate was 29%. The main toxicity was myelosuppression, Which was grade 1 or 2 in most cases. Conclusion The chemotherapy regimen of navelbine for treatment of advanced NSCLC in the elderly has good clinical efficacy and tolerability.
出处
《中国肿瘤临床与康复》
2008年第2期140-141,共2页
Chinese Journal of Clinical Oncology and Rehabilitation
